Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.31 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | CES2 | O00748 | 1/20 | 0.30 |
| ▸ | CES1 | P23141 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4607963 | 1.00 | MAPT (0.37) | MAPTKMT2AGAAALDH1A1AGTR1 | |
| SCHEMBL1393362 | 0.86 | GAA (0.35) | MAPTKMT2AGAA | |
| SCHEMBL2929573 | 0.80 | CES2 (0.36) | MAPTKMT2AALDH1A1CES2CES1 | |
| Phosphine SCHEMBL28854043 | 0.77 | CES2 (0.35) | ALDH1A1CES2CES1 | |
| SCHEMBL23899974 | 0.75 | CA9 (0.36) | MAPTKMT2AGAA | |
| SCHEMBL2948443 | 0.75 | NPC1 (0.33) | SMN1; SMN2 | |
| SCHEMBL20974621 | 0.75 | GAA (0.31) | GAA | |
| SCHEMBL7409559 | 0.75 | GAA (0.34) | MAPTKMT2AGAAALDH1A1 | |
| SCHEMBL23174468 | 0.75 | GAA (0.46) | MAPTGAA | |
| SCHEMBL17252791 | 0.75 | MYC (0.31) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119775292-A | Seven-membered fused boron-nitrogen heterocyclic compound and electroluminescent device comprising same | 华南理工大学 | 2025-04-08 | — | — | CN | disclosed |
| CN-119241481-A | Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors | 诺华股份有限公司 | 2025-01-03 | — | — | CN | disclosed |
| US-20240368134-A1 | AROMATIC COMPOUND, PHARMACEUTICAL COMPOSITION, AND APPLICATION THEREOF | SHANGHAI KYGENT PHARMACEUTICAL CO., LTD (CN) | 2024-11-07 | — | — | US | disclosed |
| EP-4442683-A1 | AROMATIC COMPOUND, PHARMACEUTICAL COMPOSITION, AND APPLICATION THEREOF | Shanghai Kygent Pharmaceutical Co., Ltd (CN) | 2024-10-09 | — | — | EP | disclosed |
| CN-115298170-B | Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors | 诺华股份有限公司 | 2024-09-27 | — | — | CN | disclosed |
| CN-116217554-B | Aromatic compound, pharmaceutical composition and application thereof | 上海栖臻医药科技有限公司 | 2024-08-09 | — | — | CN | disclosed |
| CN-116217554-A | Aromatic compound, pharmaceutical composition and application thereof | 上海栖臻医药科技有限公司 | 2023-06-06 | — | — | CN | disclosed |
| CN-115298170-A | Biaryl derivatives as inhibitors of YAP/TAZ-TEAD protein-protein interactions | 诺华股份有限公司 | 2022-11-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240368134-A1 | AROMATIC COMPOUND, PHARMACEUTICAL COMPOSITION, AND APPLICATION THEREOF | TYR, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, MITF | MAPT 985/4885KMT2A 2394/4885GAA 186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.